Industry Updates for the Psychedelics World

Psychedelics News

Industry

20 Sep 2022

MindMed Doses First Patients in Phase 1 MDMA Trial

MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances...

By Microdose NewsDesk

Industry

19 Sep 2022

Small Pharma Completes Enrollment in Phase IIa DMT Trial

Small Pharma has started the week with some positive news....

By Microdose NewsDesk

Culture, Industry

15 Sep 2022

New Survey Shows Psychedelic Use At Record High

While enthusiastic researchers, psychonauts and high-profile influencers sing the praises of psychedelics, how do everyday people interact with these once-stigmatized substances? How has the growing momentum of the psychedelic renaissance...

By Emma Stone

Industry, Press Releases

14 Sep 2022

Microdose Psychedelic Insights Partners with Concordia Annual Summit

Microdose is proud to announce its official partnership with the Concordia Annual Summit, presenting the first-ever Mental Health & Psychedelics Panel....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

12 Sep 2022

Algernon Pharmaceuticals Receives Approval for Phase 1 DMT Study

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study...

By Microdose

Industry, Law & Politics

9 Sep 2022

Microdose Brings Psychedelics to the Concordia Summit

The Concordia Annual Summit has been bringing together heads of state, leaders of the private and NGO sectors, and new and diversified perspectives for over a decade - and for...

By Microdose

Industry

8 Sep 2022

MindMed Faces Tough IP Questions (and Publishes Positive Trial Results)

MindMed’s been in the news as of late....

By Jason Najum

Industry, Science

7 Sep 2022

A Deeper Look at Ketamine for Alcohol Use Disorder

The psychedelic compound ketamine is gaining particular attention for the treatment of alcohol use disorder (AUD), with clinical studies being conducted to explore its potential....

By Elisabetta Fato

Industry

2 Sep 2022

Mydecine Sells Mindleap Health for $4 Million

Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result